Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

July SMC decisions

The Scottish Medicines Consortium has announced this month’s decisions on medicines for use in NHS Scotland. Alemtuzumab has been accepted for use for relapsing remitting multiple sclerosis in adult patients with active disease. Botulinum toxin A has been accepted for use for bladder dysfunction in patients who cannot be managed with anticholinergics or available oral therapies. Certolizumab pegol has been accepted for restricted use in combination with methotrexate for the treatment of psoriatic arthritis in adults when response to two previous disease-modifying antirheumatic drug therapies has been inadequate. Certolizumab pegol can be given as monotherapy when methotrexate is inappropriate or the the patient is intolerant to methotrexate. Dapagliflozin has been accepted for restricted use for adults with type II diabetes mellitus to improve glycaemic control. It is restricted to use in triple therapy in combination with metformin and sulphonylurea, as an alternative to dipeptidyl peptidase-4 (DPP-4) inhibitors. Rituximab has been accepted for restricted use for non-Hodgkin’s lymphoma within its licensed indication except for patients receiving maintenance treatment, where use is restricted to patients who have responded to induction therapy with rituximab plus chemotherapy. Pomalidomide, in combination with dexamethasone, has not been accepted for relapsed and refractory mutliple myeloma patients because it was not considered value for money.     

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065758

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.